Movement Alert|Twist Bioscience Corp falls 6.3% in Regular Trading, slower AI drug discovery outlook and target cuts keep pressure on shares

Market Focus11-13

On November 13, Twist Bioscience Corp fell 6.3% in Regular Trading, trading at $108.0 per share, with turnover of $9.1308 million.

The move followed continued pressure after the company’s latest outlook pointed to slower AI drug discovery growth, while several brokerages cut price targets, reinforcing a weaker post-earnings tone.

Twist Bioscience Corp reported fiscal Q4 loss of $0.32 per share on revenue of $126.6 million, both better than consensus, and guided fiscal Q1 revenue to $130 million-$132 million and fiscal revenue to $550 million-$560 million, both slightly above expectations. However, investors focused on signs of decelerating growth in AI drug discovery. Subsequent analyst actions included price-target cuts to $125 from $150, to $150 from $205, and to $150 from $212, even as some firms maintained positive ratings.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment